Condition: Squamous Cell Carcinoma of the Skin · Sponsor: Salzburger Landeskliniken
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)
This description comes directly from the study's public registry record.
Martin Laimer, MD · +4357255 · m.laimer@salk.at
Roland Lang, PhD · +4357255 · r.lang@sak.at
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Graz - LKH, Klinische Abteilung für Onkologie | Graz, Austria | Recruiting |
| LKH Innsbruck Universitätsklinik für Dermatologie und Venerologie | Innsbruck, Austria | Recruiting |
| Klinikum Klagenfurt am Wörthersee | Klagenfurt, Austria | Completed |
| Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg | Salzburg, Austria | Recruiting |
| Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften | Sankt Pölten, Austria | Recruiting |
| Med Uni Wien, Univ. Klinik für Dermatologie | Vienna, Austria | Recruiting |
| Klinikum Wels-Grieskirchen GmbH | Wels, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04204837